Literature DB >> 1692830

Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells.

A Gougos1, M Letarte.   

Abstract

Endoglin is a major glycoprotein of human vascular endothelium. As observed with monoclonal antibody 44G4, the distribution of endoglin is restricted to endothelial cells in all tissues except bone marrow. cDNA clones were isolated from an endothelial cell lambda gt11 cDNA library using a rabbit antibody prepared against endoglin purified from placenta. Eleven antibody-positive and cross-hybridizing clones were obtained; reactivity with endothelial cell 3.4-kilobase mRNA transcript was observed. The N-terminal sequence of placental endoglin was determined and found within the deduced protein sequence, thus confirming the identity of the cDNA and revealing a partial signal peptide. Endoglin is a type I integral membrane protein of Mr = 68,051 with an extracellular region of 561 amino acids, a hydrophobic transmembrane domain, and a 47-residue cytoplasmic tail. There are four potential N-linked glycosylation sites in the N-terminal domain and a probable O-glycan domain rich in Ser and Thr residues proximal to the membrane-spanning domain. Data base searches revealed that endoglin is a novel protein. The sequence contains an RGD tripeptide (374-376), the first identified on a surface protein of endothelium. The presence of RGD, a key recognition structure in cellular adhesion, suggests a critical role for endoglin in the binding of endothelial cells to integrins and/or other RGD receptors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1692830

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  109 in total

Review 1.  Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms.

Authors:  C L Shovlin; M Letarte
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

Review 2.  Hereditary hemorrhagic telangiectasia: A model for blood vessel growth and enlargement.

Authors:  B S Jacobson
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

Review 3.  Physiology of angiogenesis.

Authors:  H Kurz
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

Review 4.  The role of angiogenesis in rheumatoid arthritis: recent developments.

Authors:  A E Koch
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

5.  Endoglin expression level discriminates long-term hematopoietic from short-term clonogenic progenitor cells in the aorta.

Authors:  Marion Roques; Charles Durand; Rodolphe Gautier; Pierre-Yves Canto; Laurence Petit-Cocault; Laurent Yvernogeau; Dominique Dunon; Michèle Souyri; Thierry Jaffredo
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

6.  Targeting endoglin, an auxiliary transforming growth factor β coreceptor, to prevent fibrosis and heart failure.

Authors:  Ivor J Benjamin
Journal:  Circulation       Date:  2012-05-16       Impact factor: 29.690

7.  Endoglin expression is reduced in normal vessels but still detectable in arteriovenous malformations of patients with hereditary hemorrhagic telangiectasia type 1.

Authors:  A Bourdeau; U Cymerman; M E Paquet; W Meschino; W C McKinnon; A E Guttmacher; L Becker; M Letarte
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

8.  Endoglin and Alk5 regulate epithelial-mesenchymal transformation during cardiac valve formation.

Authors:  Melania E Mercado-Pimentel; Antony D Hubbard; Raymond B Runyan
Journal:  Dev Biol       Date:  2006-12-23       Impact factor: 3.582

Review 9.  Structural Biology and Evolution of the TGF-β Family.

Authors:  Andrew P Hinck; Thomas D Mueller; Timothy A Springer
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-12-01       Impact factor: 10.005

10.  In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis.

Authors:  Yunan Yang; Yin Zhang; Hao Hong; Glenn Liu; Bryan R Leigh; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-04       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.